Want to see EW full AI Analyst Report?

Edwards Lifesciences (EW) Stock Forecast & Price Target

1,975 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EW Analyst Ratings

Strong Buy

14 Buy

4 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Edwards

Lifesciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EW Stock 12 Month Forecast

Average Price Target

$101.20

▲(24.95% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is $101.20 with a high forecast of $110.00 and a low forecast of $85.00. The average price target represents a 24.95% change from the last price of $80.99.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"$75","84":"$84","93":"$93","102":"$102","111":"$111"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":101.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$101.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$85.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,84,93,102,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.99,93.3753846153846,94.76076923076923,96.14615384615384,97.53153846153846,98.91692307692307,100.30230769230769,101.6876923076923,103.07307692307693,104.45846153846153,105.84384615384616,107.22923076923077,108.61461538461538,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.99,92.69846153846153,93.40692307692308,94.11538461538461,94.82384615384615,95.5323076923077,96.24076923076923,96.94923076923077,97.6576923076923,98.36615384615385,99.07461538461538,99.78307692307692,100.49153846153847,{"y":101.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,91.99,91.45230769230768,90.91461538461537,90.37692307692308,89.83923076923077,89.30153846153846,88.76384615384615,88.22615384615385,87.68846153846154,87.15076923076923,86.61307692307692,86.07538461538462,85.53769230769231,{"y":85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":77.18,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.31,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.45,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.27,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.65,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.18,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.26,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.98,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.16,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.99,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$110.00

Average Price Target$101.20

Lowest Price Target$85.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anthony Petrone

Mizuho Securities

$100→$105

Buy

29.65%

Upside

Reiterated

07/15/26

Edwards Lifesciences price target raised to $105 from $100 at MizuhoEdwards Lifesciences price target raised to $105 from $100 at Mizuho

Shagun Singh Chadha

RBC Capital

$100→$110

Buy

35.82%

Upside

Reiterated

07/13/26

Edwards Lifesciences price target raised to $110 from $100 at RBC CapitalEdwards Lifesciences price target raised to $110 from $100 at RBC Capital

Marie Thibault

BTIG

$110

Buy

35.82%

Upside

Reiterated

07/10/26

BTIG Remains a Buy on Edwards Lifesciences (EW)

Joanne Wuensch

Citi

$101→$110

Buy

35.82%

Upside

Reiterated

07/08/26

Citi Keeps Their Buy Rating on Edwards Lifesciences (EW)

Vijay Kumar

Evercore ISI

$93→$100

Buy

23.47%

Upside

Reiterated

07/06/26

Edwards Lifesciences price target raised to $100 from $93 at Evercore ISIEdwards Lifesciences price target raised to $100 from $93 at Evercore ISI

Josh Jennings

TD Cowen

$104

Buy

28.41%

Upside

Reiterated

06/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (NYSE: EW), Encompass Health (NYSE: EHC) and Moderna (NASDAQ: MRNA)

Richard Newitter

Truist Financial

―

Hold

―

Reiterated

06/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (NYSE: EW), High Tide (NASDAQ: HITI) and Option Care Health (NASDAQ: OPCH)

Mike Kratky

Leerink Partners

$87

Hold

7.42%

Upside

Assigned

06/16/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and Spyre Therapeutics (NASDAQ: SYRE)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

06/16/26

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Qiagen (NYSE: QGEN) and Edwards Lifesciences (NYSE: EW)

David Roman

Goldman Sachs

$98

Buy

21.00%

Upside

Reiterated

06/15/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Vertex Pharmaceuticals (NASDAQ: VRTX) and Kyowa Kirin Co (Other OTC: KYKOF)

Travis Steed

Bank of America Securities

$100

Buy

23.47%

Upside

Reiterated

06/15/26

Edwards Lifesciences Buy Rating Reaffirmed as Favorable TAVR Policy Update Supports Growth and $100 Price Target Maintained

Matthew Taylor

Jefferies

$102

Buy

25.94%

Upside

Reiterated

05/27/26

Jefferies Remains a Buy on Edwards Lifesciences (EW)

David Toung

Argus Research

―

Buy

―

Reiterated

05/21/26

Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Eli Lilly & Co (LLY)

Adam Maeder

Piper Sandler

$100

Buy

23.47%

Upside

Reiterated

05/05/26

Edwards Lifesciences (EW) Gets a Buy from Piper Sandler

David Rescott

Robert W. Baird

$85→$87

Hold

7.42%

Upside

Reiterated

04/24/26

Edwards Lifesciences price target raised to $87 from $85 at BairdEdwards Lifesciences price target raised to $87 from $85 at Baird

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anthony Petrone

Mizuho Securities

$100→$105

Buy

29.65%

Upside

Reiterated

07/15/26

Edwards Lifesciences price target raised to $105 from $100 at MizuhoEdwards Lifesciences price target raised to $105 from $100 at Mizuho

Shagun Singh Chadha

RBC Capital

$100→$110

Buy

35.82%

Upside

Reiterated

07/13/26

Edwards Lifesciences price target raised to $110 from $100 at RBC CapitalEdwards Lifesciences price target raised to $110 from $100 at RBC Capital

Marie Thibault

BTIG

$110

Buy

35.82%

Upside

Reiterated

07/10/26

BTIG Remains a Buy on Edwards Lifesciences (EW)

Joanne Wuensch

Citi

$101→$110

Buy

35.82%

Upside

Reiterated

07/08/26

Citi Keeps Their Buy Rating on Edwards Lifesciences (EW)

Vijay Kumar

Evercore ISI

$93→$100

Buy

23.47%

Upside

Reiterated

07/06/26

Edwards Lifesciences price target raised to $100 from $93 at Evercore ISIEdwards Lifesciences price target raised to $100 from $93 at Evercore ISI

Josh Jennings

TD Cowen

$104

Buy

28.41%

Upside

Reiterated

06/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (NYSE: EW), Encompass Health (NYSE: EHC) and Moderna (NASDAQ: MRNA)

Richard Newitter

Truist Financial

―

Hold

―

Reiterated

06/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Edwards Lifesciences (NYSE: EW), High Tide (NASDAQ: HITI) and Option Care Health (NASDAQ: OPCH)

Mike Kratky

Leerink Partners

$87

Hold

7.42%

Upside

Assigned

06/16/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW) and Spyre Therapeutics (NASDAQ: SYRE)

Brandon Vazquez

William Blair

―

Buy

―

Reiterated

06/16/26

Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK), Qiagen (NYSE: QGEN) and Edwards Lifesciences (NYSE: EW)

David Roman

Goldman Sachs

$98

Buy

21.00%

Upside

Reiterated

06/15/26

Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (NYSE: EW), Vertex Pharmaceuticals (NASDAQ: VRTX) and Kyowa Kirin Co (Other OTC: KYKOF)

Travis Steed

Bank of America Securities

$100

Buy

23.47%

Upside

Reiterated

06/15/26

Edwards Lifesciences Buy Rating Reaffirmed as Favorable TAVR Policy Update Supports Growth and $100 Price Target Maintained

Matthew Taylor

Jefferies

$102

Buy

25.94%

Upside

Reiterated

05/27/26

Jefferies Remains a Buy on Edwards Lifesciences (EW)

David Toung

Argus Research

―

Buy

―

Reiterated

05/21/26

Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), Eli Lilly & Co (LLY)

Adam Maeder

Piper Sandler

$100

Buy

23.47%

Upside

Reiterated

05/05/26

Edwards Lifesciences (EW) Gets a Buy from Piper Sandler

David Rescott

Robert W. Baird

$85→$87

Hold

7.42%

Upside

Reiterated

04/24/26

Edwards Lifesciences price target raised to $87 from $85 at BairdEdwards Lifesciences price target raised to $87 from $85 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TARAProtara Therapeutics

BKDBrookdale Senior Living

EYPTEyePoint Pharmaceuticals

ZVRAZevra Therapeutics

DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Edwards Lifesciences

3 Months

Adam MaederPiper Sandler

Success Rate

18/27 ratings generated profit

Average Return

+1.83%

Copying Adam Maeder's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +1.83% per trade.

1 Year

Adam MaederPiper Sandler

Success Rate

22/27 ratings generated profit

Average Return

+10.15%

Copying Adam Maeder's trades and holding each position for 1 Year would result in 81.48% of your transactions generating a profit, with an average return of +10.15% per trade.

2 Years

Larry BiegelsenWells Fargo

Success Rate

15/21 ratings generated profit

Average Return

+13.34%

Copying Larry Biegelsen's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +13.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EW Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EW has received 28 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. EW average Analyst price target in the past 3 months is 101.20.

Each month's total comprises the sum of three months' worth of ratings.

EW Financial Forecast

EW Earnings Forecast

Next quarter’s earnings estimate for EW is $0.74 with a range of $0.73 to $0.78. The previous quarter’s EPS was $0.78. EW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Sales Forecast

Next quarter’s sales forecast for EW is $1.70B with a range of $1.68B to $1.72B. The previous quarter’s sales results were $1.65B. EW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year EW has Performed in-line its overall industry.

EW Stock Forecast FAQ

What is EW’s average 12-month price target, according to analysts?

Based on analyst ratings, Edwards Lifesciences Corp.’s 12-month average price target is 101.20.

What is EW’s upside potential, based on the analysts’ average price target?

Edwards Lifesciences Corp. has 24.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EW a Buy, Sell or Hold?

Edwards Lifesciences Corp. has a consensus rating of Strong Buy which is based on 14 buy ratings, 4 hold ratings and 0 sell ratings.

What is Edwards Lifesciences Corp.’s price target?

The average price target for Edwards Lifesciences Corp. is 101.20. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $85.00. The average price target represents 24.95% Increase from the current price of $80.99.

What do analysts say about Edwards Lifesciences Corp.?

Edwards Lifesciences Corp.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of EW?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Edwards Lifesciences (EW) Stock Forecast & Price Target

EW Analyst Ratings

EW Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Edwards Lifesciences

EW Analyst Recommendation Trends

EW Financial Forecast

EW Earnings Forecast

EW Sales Forecast

EW Stock Forecast FAQ

Detailed List of Analyst Forecasts